AstraZeneca's Q3 2024 earnings exceeded expectations, with a revenue increase of 18%, signaling healthy demand for its products, especially in oncology and rare diseases.
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not yet in overbought territory, suggesting there’s still room for growth
Trendline support: The stock is currently around the trendline support
STOCK ANALYSIS
Support Levels: AZN’s stock is trading close to its key support levels, around $66.26, and has shown resilience above the $60 mark, which historically has been a strong support zone. The stock is likely to maintain upward pressure if it holds above this level
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not yet in overbought territory, suggesting there’s still room for growth
Trendline support: The stock is currently around the trendline support
STOCK ANALYSIS
Support Levels: AZN’s stock is trading close to its key support levels, around $66.26, and has shown resilience above the $60 mark, which historically has been a strong support zone. The stock is likely to maintain upward pressure if it holds above this level
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.